Reclast Articles
Overview of Novartis' patent losses from GlobalData
11 October 2012
Denosumab superior to zoledronic acid for breast cancer patients with bone metastases
15 August 2012
Two US FDA advisory panels say osteoporosis drugs need label changes
12 September 2011
Novartis once-yearly Reclast preserves bone mass, provides fracture protection in postmenopausal osteoporosis, long term data show
18 October 2010
USA’s FDA calls for label changes on bisphosphonates due to possible increased risk of thigh bone fracture
14 October 2010
Bisphosphonates under scrutiny in Europe over link to stress fractures
28 September 2010
One cheer for Pfizer’s Fablyn
26 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
Aclasta more effective than risedronate
14 April 2009
FDA finds no AF link for bisphosphonates
24 November 2008
Novartis gets extra EU authorization for Aclasta
6 October 2008
Roche's reclast gets expanded US label
16 June 2008
Correction: Novartis' Reclast
16 June 2008
FDA warns: severe pain with bisphosphonates
14 January 2008
Novartis' Aclasta cleared in the EU
15 October 2007
Novartis' Reclast approved by US FDA
20 August 2007
Novartis
14 May 2007
FDA approves Novartis' Reclast for Paget's
23 April 2007
Annual Aclasta cuts risk of osetoportic fracture
25 September 2006
Showing 1-28 of 28 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
